

CST Bulletin – September 1st, 2026

BC Cancer ST Program Updates for September 2026

AFFECTED APPLICATION(S)	PowerChart
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - Do not** use the Copy Forward functionality to ensure that the updates apply.



- IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below.

Protocols: ULKBLIN, ULKBLINF, ULKMRDBLIN

Cycles/PowerPlans:

- ONCP LK ULKBLINF Cycle 1 (Inpatient and Outpatient)
- ONCP LK ULKBLINF Cycle 2 (Inpatient and Outpatient)
- ONCP LK ULKBLINF Cycles 3 to 4 (Inpatient and Outpatient)
- ONCP LK ULKBLIN Cycle 1 (Inpatient and Outpatient)
- ONCP LK ULKBLIN Cycle 2 (Inpatient and Outpatient)
- ONCP LK ULKBLIN Cycles 3 to 5 (Inpatient and Outpatient)
- ONCP LK ULKMRDBLIN Cycle 1 (Inpatient and Outpatient)
- ONCP LK ULKMRDBLIN Cycle 2 (Inpatient and Outpatient)
- ONCP LK ULKMRDBLIN Cycles 3 to 4 (Inpatient and Outpatient)

Changes:

ULKBLIN, ULKBLINF, ULKMRDBLIN Cycle 1 (Inpatient and Outpatient)

Chemotherapy Related Labs Phase

- **Removed** *Electrolytes Panel (Na, K, Cl, CO2)*
- **Added** *Sodium and Potassium Panel – Blood, Routine, Collection: T;N, qdaily for 28 day*

ONCP LK ULKBLIN Cycle 1 (Inpatient and Outpatient) - Cycle 1, Chemotherapy Related Labs (Planned Pending)		
☒	 CBC and Differential	Blood, Routine, qdaily for 28 day
☒	 Sodium and Potassium Panel	Blood, Routine, Collection: T;N, qdaily for 28 day

Chemotherapy Phase

- Unselected diphenhydrAMINE
- Added and preselected loratadine – 10 mg, PO, once oncology, drug form: tab, Between 30 and 60 minutes prior to treatment. Day 1 (offset by -30 Minutes)
- Linked component added so that only 1 of diphenhydrAMINE or loratadine can be ordered

☐	  diphenhydrAMINE	▼ Select an order sentence
☒	  loratadine	10 mg, PO, once oncology, drug form: tab Between 30 and 60 minutes prior to treatment. Day 1

ONCP LK ULKBLIN Cycle 1 (Inpatient and Outpatient)

Chemotherapy Related Labs Phase

- **Added** yellow note 'If clinically indicated:'
- **Added** lab orders for *Hepatitis B Core Antibody Total BCCDC*, *Hepatitis B Surface Antigen BCCDC*, *Hepatitis B Surface Antibody BCCDC*, *Hepatitis B Viral Load (Rx monitoring)* and *Herpes Simplex Virus 1/2 Antibody IgG* – Blood, Routine, Collection: T;N, once.

If clinically indicated:		
☐	 Hepatitis B Core Antibody Total BCCDC	Blood, Routine, Collection: T;N, once
☐	 Hepatitis B Surface Antigen BCCDC	Blood, Routine, Collection: T;N, once
☐	 Hepatitis B Surface Antibody BCCDC	Blood, Routine, Collection: T;N, once
☐	 Hepatitis B Viral Load (Rx monitoring)	Blood, Routine, Collection: T;N, once
☐	 Herpes Simplex Virus 1/2 Antibody IgG	Blood, Routine, Collection: T;N, once

Chemotherapy Related Orders Phase

- **Added** a duration of 7 days to allpurinol.
- **Removed** rasburicase.

☒	 sodium chloride 0.9% (sodium chloride 0.9% (NS) continuous infusion)	order rate: 100 mL/h, IV, drug form: bag, No Start on Day 1 and reassess after Day 3
☒	 allopurinol	300 mg, PO, qdaily, order duration: 7 day, drug form: tab
☒	 sulfamethoxazole-trimethoprim (cotrimox...	160 mg, PO, BIDMonThu, drug form: tab

ONCP LK ULKBLIN Cycle 1 (Inpatient and Outpatient)

Chemotherapy Related Labs Phase

- **Added** yellow note 'If clinically indicated:'
- **Added** lab orders for *Hepatitis B Core Antibody Total BCCDC*, *Hepatitis B Surface Antigen BCCDC*, *Hepatitis B Surface Antibody BCCDC*, *Hepatitis B Viral Load (Rx monitoring)* and *Herpes Simplex Virus 1/2 Antibody IgG* – Blood, Routine, Collection: T;N, once.

If clinically indicated:		
☐	 Hepatitis B Core Antibody Total BCCDC	Blood, Routine, Collection: T;N, once
☐	 Hepatitis B Surface Antigen BCCDC	Blood, Routine, Collection: T;N, once
☐	 Hepatitis B Surface Antibody BCCDC	Blood, Routine, Collection: T;N, once
☐	 Hepatitis B Viral Load (Rx monitoring)	Blood, Routine, Collection: T;N, once
☐	 Herpes Simplex Virus 1/2 Antibody IgG	Blood, Routine, Collection: T;N, once

Labs Phase

- **Removed** INR

- **Removed** Fibrinogen Level
- **Removed** C-Reactive Protein High Sensitivity

ONCP LK ULKMRDBLIN Cycle 1 (Inpatient and Outpatient)

Chemotherapy Related Labs Phase

- **Added** yellow note 'If clinically indicated:' above existing unselected Hepatitis B labwork
- **Added** *Hepatitis B Viral Load (Rx monitoring)* - Blood, Routine, Collection:T;N, once

If clinically indicated:		
☐	☒ Hepatitis B Core Antibody Total BCCDC	Blood, Routine, once
☐	☒ Hepatitis B Surface Antigen BCCDC	Blood, Routine, once
☐	☒ Hepatitis B Surface Antibody BCCDC	Blood, Routine, once
☐	☒ Herpes Simplex Virus 1/2 Antibody IgG	Blood, Routine, once
☐	☒ Hepatitis B Viral Load (Rx monitoring)	Blood, Routine, once

Labs Phase

- **Removed** INR
- **Removed** Fibrinogen Level
- **Removed** C-Reactive Protein High Sensitivity

ULKBLIN, ULKBLINF, ULKMRDBLIN Cycle 2 (Inpatient and Outpatient)

Chemotherapy Related Labs Phase

- **Removed** *Electrolytes Panel (Na, K, Cl, CO2).*
- **Added** *Sodium and Potassium Panel* – Blood, Routine, qdaily for 28 day.

ONCP LK ULKBLIN Cycle 2 (Inpatient and Outpatient) - Cycle 2, Chemotherapy Related Labs (Planned Pending)		
☒	☒ CBC and Differential	Blood, Routine, qdaily for 28 day
☒	☒ Sodium and Potassium Panel	Blood, Routine, qdaily for 28 day

Chemotherapy Phase

- **Unselected** diphenhydramine.
- **Added** and preselected loratadine – 10 mg, PO, once oncology, drug form: tab, Between 30 and 60 minutes prior to treatment. Day 1 (offset by -30 Minutes).
- Linked component added so that only 1 of diphenhydrAMINE or loratadine can be ordered.

☐	 diphenhydrAMINE	Select an order sentence
☒	 loratadine	10 mg, PO, once oncology, drug form: tab Between 30 and 60 minutes prior to treatment. Day 1

- **Added** a green banner Hydration.
- **Added** a preselected sodium chloride 0.9% bolus – 1,000 mL, IV, once, administer over:2 hour, drug form:bag, Day 1.

	Hydration	
☒	 sodium chloride 0.9% (sodium chloride 0.9% (NS) bolus)	1,000 mL, IV, once, administer over: 2 hour, drug form: bag Day 1

- **Updated** Vital Signs order to read 'Vital signs immediately before the start of the infusion, then Q1H for the first 4 hours of the infusion on Day 1, then vital signs routine if patient is stable'.
- **Updated** Oncology Communication Order to read 'Signature sheet daily or with each Daycare visit'.

☒	☒ Vital Signs	Vital signs immediately before the start of the infusion, then Q1H for the first 4 hours of the infusion on Day 1, then vital signs routine if patient is stable
☒	☒ Oncology Communication Order	Signature sheet daily or with each Daycare visit

Chemotherapy Related Orders Phase

- **Removed** sodium chloride 0.9% continuous infusion.

Prescriptions Phase

- **Updated** valacyclovir dispense quantity to 30 days.

☐	 valACYclovir	500 mg, PO, BID, drug form: tab, dispense qty: 30 day
--------------------------	--	---

Labs Phase

- **Added** preselected orders for CBC and Differential, Electrolytes Panel Outpatient, Phosphate Level, Calcium Level, Urea Level, Creatinine and Estimated GFR, Alanine Aminotransferase, Alkaline Aminotransferase, Gamma Glutamyl Transferase, Bilirubin Total and Direct, Albumin Level, Lactate Dehydrogenase, Lipase, INR, Fibrinogen Level and C-Reactive Protein High Sensitivity to Day 1 on the treatment Schedule and 2 Day 2 minus Lipase.
- **Added** yellow note 'If clinically indicated:' above existing unselected Hepatitis B lab work.
- **Added** Hepatitis B Viral Load (Rx monitoring) - Blood, Routine, Collection: T;N, once.

ONCP LK ULKBLIN Cycle 2 (Inpatient and Outpatient) - Cycle 2, Labs Day 1 to 2, 5, 9, 13, 17, 21, 25, 29) (Future)		
☒	☒ CBC and Differential	Blood, once, Order for future visit
☒	☒ Sodium and Potassium Panel (Electrolytes ...	Blood, once, Order for future visit
☒	☒ Uric Acid	Blood, once, Order for future visit
☒	☒ Phosphate Level	Blood, once, Order for future visit
☒	☒ Calcium Level	Blood, once, Order for future visit
☒	☒ Urea Level	Blood, once, Order for future visit
☒	☒ Creatinine and Estimated GFR	Blood, once, Order for future visit
☒	☒ Alanine Aminotransferase	Blood, once, Order for future visit
☒	☒ Alkaline Phosphatase	Blood, once, Order for future visit
☒	☒ Gamma Glutamyl Transferase	Blood, once, Order for future visit
☒	☒ Bilirubin Total and Direct	Blood, once, Order for future visit
☒	☒ Albumin Level	Blood, once, Order for future visit
☒	☒ Lactate Dehydrogenase	Blood, once, Order for future visit
☒	☒ Lipase	Blood, once, Order for future visit
☒	☒ INR	Blood, once, Order for future visit
☒	☒ Fibrinogen Level	Blood, once, Order for future visit
☒	☒ C-Reactive Protein High Sensitivity	Blood, once, Order for future visit
If clinically indicated:		
☐	☒ Hepatitis B Viral Load (Rx monitoring)	Blood, once, Order for future visit

Scheduling Phase

- Added a Follow-Up – Clinic – Nurse Visit – Within 2 Weeks, In Person/Clinic, VGH BMT Daycare Nursing Visit, LK (Protocol name) – Day 2 bloodwork and assessment, Day 2

☒	☒ Follow Up - Clinic - Nurse Visit	Within 2 Weeks, In Person/Clinic, VGH BMT Daycare Nursing Visit, LK ULKBLIN - Day 2 bloodwork and assessment Day 2
-------------------------------------	--	---

ONCP LK ULKBLIN Cycle 2 (Inpatient and Outpatient)

- INR updated to Blood, Routine, qdaily for 2 day and added to Day 2 treatment schedule .
- Fibrinogen Level updated to Blood, Routine, qdaily for 2 day and added to Day 2 treatment schedule .
- C-Reactive Protein High Sensitivity updated to Blood, Routine, qdaily for 2 day and added to Day 2 treatment schedule.
- Added yellow note 'If clinically indicated:' below CRP.
- Added Hepatitis B Viral Load (Rx monitoring) - Blood, Routine, once.

☒	☒ INR	Blood, Routine, qdaily for 2 day
☒	☒ Fibrinogen Level	Blood, Routine, qdaily for 2 day
☒	☒ C-Reactive Protein High Sensitivity	Blood, Routine, qdaily for 2 day
If clinically indicated:		
☐	☒ Hepatitis B Viral Load (Rx monitoring)	Blood, Routine, once

ONCP LK ULKMRDBLIN Cycle 2 (Inpatient and Outpatient)

Chemotherapy Related Labs Phase

- **Removed** Uric Acid.

Labs Phase

- **Removed** Uric Acid.

ULKBLIN, ULKBLINF, ULKMRDBLIN Cycles 3+ (Inpatient and Outpatient)

Chemotherapy Phase

- **Unselected** diphenhydrAMINE.
- **Added** and preselected loratadine – 10 mg, PO, once oncology, drug form: tab, Between 30 and 60 minutes prior to treatment. Day 1 (offset by -30 Minutes).
- **Linked** component added so that only 1 of diphenhydrAMINE or loratadine can be ordered.

☐	 diphenhydrAMINE	▼ Select an order sentence
☒	 loratadine	10 mg, PO, once oncology, drug form: tab Between 30 and 60 minutes prior to treatment. Day 1

- **Updated** Oncology Communication Order to read 'Signature sheet daily or with each Daycare visit'.

☒	 Oncology Communication Order	Signature sheet daily or with each Daycare visit
-------------------------------------	--	--

Prescriptions Phase:

- **Updated** valacyclovir dispense quantity to 30 days.

☐	 valACYclovir	500 mg, PO, BID, drug form: tab, dispense qty: 30 day
--------------------------	--	---

Labs Phase:

- **Added** yellow note 'If clinically indicated:'
- **Added** Hepatitis B Viral Load (Rx monitoring) - Blood, once, Order for future visit

 If clinically indicated:		
☐	 Hepatitis B Viral Load (Rx monitoring)	Blood, once, Order for future visit

ONCP LK ULKBLIN Cycles 3 to 5 (Inpatient and Outpatient)

Labs Phase:

- **Removed** Chloride Level
- **Removed** Bicarbonate
- **Removed** Uric Acid

ONCP LK ULKBLINF Cycles 3 to 4 (Inpatient and Outpatient)

Labs Phase:

- **Removed** INR
- **Removed** Fibrinogen Level
- **Removed** C-Reactive Protein High Sensitivity

ONCP LK ULKMRDBLIN Cycles 3 to 4 (Inpatient and Outpatient)

Labs Phase:

- **Removed** Uric Acid

Versioning: Yes

Jira: CST-378055

Protocols: LYCHPBV, LYPOLABR, LYPOLARCHP, LYAVDBV, LYBVAVDBV

Cycles/PowerPlans:

- ONCP LY LYCHPBV Cyclophosphamide Hyperbilirubinemia Option
- ONCP LY LYCHPBV DOXOrubicin Option
- ONCP LY LYCHPBV Etoposide Cardiac Dysfunction Option
- ONCP LY LYPOLABR Cycle 1
- ONCP LY LYPOLABR Cycles 2 to 6
- ONCP LY LYPOLARCHP Cyclophosphamide Hyperbilirubinemia Option Cycle 1
- ONCP LY LYPOLARCHP DOXOrubicin Option Cycle 1
- ONCP LY LYPOLARCHP Etoposide Cardiac Dysfunction Option Cycle 1
- ONCP LY LYAVDBV Cyclophosphamide Hyperbilirubinemia Option
- ONCP LY LYAVDBV DOXOrubicin Option
- ONCP LY LYAVDBV Etoposide Cardiac Dysfunction Option
- ONCP LY LYBVAVDBV Cyclophosphamide Hyperbilirubinemia Option Cycles 3 to 8
- ONCP LY LYBVAVDBV DOXOrubicin Option Cycles 3 to 8
- ONCP LY LYBVAVDBV Etoposide Cardiac Dysfunction Option Cycles 3 to 8

Changes:

- **Updated** yellow note in the Chemotherapy Phase under 'Procedural/Schedulable Order' to add "or pegfilgrastim"

Component	Status	Dose ...	Details
ONCP LY LYCHPBV Cyclophosphamide Hyperbilirubinemia Option - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 08-Aug-2026 08:00 PDT - 21 Days			
Link to Protocol: Treatment of CD30-Positive Peripheral T-Cell Lymphoma (PTCL) with DOXOrubicin, Cyclophosphamide, predniSONE (CHP) and Brentuximab Vedotin			
Revised: 1 Sept 2026			
Procedural/Schedulable Orders			
Book filgrastim or pegfilgrastim (G-CSF) SC teaching and first dose			
Additional Orders			
Any additional orders will be displayed below. Please review and adjust scheduled administration time as needed			
ONCP LY LYCHPBV Cyclophosphamide Hyperbilirubinemia Option - Cycle 1, Prescriptions (Future Pending) *Est. 08-Aug-2026 08:00 PDT			

ONCP LY LYAVDBV Cyclophosphamide Hyperbilirubinemia Option, ONCP LY LYAVDBV DOXOrubicin Option and ONCP LY LYAVDBV Etoposide Cardiac Dysfunction Option

- **Updated** Special Instructions in all the following scheduling orders to "Cycle 1 Day TBD: schedule patient education and first injection. Please contact provider for filgrastim or pegfilgrastim start date". Updated scheduling priority to "Within 1 Day":
 - Schedule BCC Teach – Subcutaneous Injection
 - Schedule BCC PG Teach – Subcutaneous Injection
 - Schedule BCC AB Teach – Subcutaneous Injection
 - Schedule BCC SU Teach – Subcutaneous Injection
 - Schedule BCC VI Teach – Subcutaneous Injection

ONCP LY LYAVDBV Cyclophosphamide Hyperbilirubinemia Option - Cycle 1, Scheduling (Initiated Pending)			
☒	Schedule BCC Teach - Subcutaneous Injection	BCC VA ACU FM, Patient education and first injection, Cycle 1 Day TBD: schedule patient education and first injection. Please contact provider for filgrastim or pegfilgrastim start date, Within 1 Day	
☒	Go to Chemo Calendar to send next cycle to scheduling wait list	Schedule BCC Teach - Subcutaneous Injection	
		Details: BCC VA ACU FM, Patient education and first injection, Cycle 1 Day TBD: schedule patient education and first injection. Please contact provider for filgrastim or pegfilgrastim start date, Within 1 Day	

- **Updated** Special Instructions in all the following scheduling orders to "Cycle 1 Day TBD: schedule patient education and first injection. Please contact provider for filgrastim or pegfilgrastim start date"
 - Schedule RHS Teach – Subcutaneous Injection
 - Schedule qGH Teach – Subcutaneous Injection
 - Schedule LGH Teach – Subcutaneous Injection

- Schedule SGH Teach – Subcutaneous Injection
- Schedule SSH Teach – Subcutaneous Injection

Component	Status	Dose ...	Details
ONCP LY LYAVDBV Cyclophosphamide Hyperbilirubinemia Option - Cycle 1, Scheduling (Initiated Pending)			
☒ Schedule RHS Teach - Subcutaneous Injection			RHS Cancer Care, Patient education and first injection, Cycle 1 Day TBD: schedule patient education and first injection.
☒ Go to Chemo Calendar to send next cycle to scheduling wait list			Schedule RHS Teach - Subcutaneous Injection
Details: RHS Cancer Care, Patient education and first injection, Cycle 1 Day TBD: schedule patient education and first injection. Please contact provider for filgrastim or pegfilgrastim start date, As Per Special Instructions			

Versioning: Y

Jira: CST-376739

Protocols: GIGFLODOC

Cycles/PowerPlans:

- ONCP GI GIGFLODOC

Changes:

- **Updated** all orders for **Schedule BCC Teach – Subcutaneous Injection**. Update Cycle 1 Day 5 to Cycle 1 Day 3, order sentence now reads 'Patient education and first injection, **Cycle 1 Day 3**: schedule patient education and first injection, Within 1 Week'.

ONCP GI GIGFLODOC - Cycle 1, Scheduling (Initiated Pending) 18-Aug-2026 08:00 PDT			
☒ Infusion Chemotherapy Visit	Within 2 Weeks, Cycle 1: Chair time 285 minutes; Nurse time 75 minutes. Cycle 2: Nurse time 60 minutes, Chair Time: 255 minutes, Nurse Time: 45 minutes, ONCP GI GIGFLODOC		
☒ Follow Up - Clinic - Oncology On Treatment	Day 1	Physician Specialty: Medical Oncology, Tumor Group: Gastrointestinal	
☒ Follow Up - Clinic - Nurse Telephone Line ...	As Per Special Instructions, Phone, Nurse Assessment - ST Treatment, Treatment related side effects (refer to protocol for more information), Schedule nurse phone call week		
☒ Schedule BCC Teach - Subcutaneous Injecti...	BCC VA ACU FM, Patient education and first injection, Cycle 1 Day 3: schedule patient education and first injection, Within 1 Week		

Versioning: Yes

Jira: CST-380698

Protocols: UGUPLVT

Cycles/PowerPlans:

- ONCP GU UGUPLVT

Changes:

- **Lab phase updated** - Labs should be listed as: Week 3, 5, 9, 11, 15, 17, 21, 23, 27, 29, 33.

ONCP GU UGUPLVT - Cycle 1, Labs (Week 3, 5, 9, 11, 15, 17, 21, 23, 27, 29, 33) (Future Pending) *Est. 18-Aug-2026 08:00 PDT - 52 Weeks		
☒	☒ CBC and Differential	Blood, once, Order for future visit
☒	☒ Creatinine and Estimated GFR	Blood, once, Order for future visit
☒	☒ Albumin Level	Blood, once, Order for future visit
☒	☒ Bilirubin Total	Blood, once, Order for future visit
☒	☒ Alanine Aminotransferase	Blood, once, Order for future visit
☒	☒ Alkaline Phosphatase	Blood, once, Order for future visit
☒	☒ PSA - Known/Suspected Prostate Cancer	Blood, once, Order for future visit
If clinically indicated:		
☐	☒ Sodium and Potassium Panel (Electrolytes ...	Blood, once, Order for future visit
☐	☒ Calcium Level	Blood, once, Order for future visit

- **Added 6 additional orders for Follow-Up – Clinic – Oncology On Treatment orders with offsets.**
- **Updated the special instructions and offsets on the existing 5 Follow-Up – Clinic – Oncology On Treatment orders.**

Select below scheduling orders for medical oncology follow ups		
☒	☒ Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #1 - Week 1. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +28 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #2 - Week 4. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +42 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #2 - Week 6. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +70 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #3 - Week 10. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +84 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #3 - Week 12. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +112 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #4 - Week 16. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +136 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #4 - Week 18. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +154 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #5 - Week 22. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +168 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #5 - Week 24. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +196 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #6 - Week 28. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.
☒	☒ +210 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Remote Provincial Clerk to Process ONLY. Prior to Dose #6 - Week 30. Lu 177 (PLUVICTO) treatment, Physician Specialty: Medical Oncology.

- **Added 6 additional orders for Follow-Up – Clinic – Radiation Oncology orders with offsets.**
- **Updated the special instructions and offsets on the existing 5 Follow-Up – Clinic – Radiation Oncology orders.**

Select below scheduling orders for radiation oncology follow ups		
☐	☒ Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #1 - Week 1. Lu 177 (PLUVICTO) treatment
☐	☒ +28 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #2 - Week 4. Lu 177 (PLUVICTO) treatment
☐	☒ +42 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #2 - Week 6. Lu 177 (PLUVICTO) treatment
☐	☒ +70 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #3 - Week 10. Lu 177 (PLUVICTO) treatment
☐	☒ +84 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #3 - Week 12. Lu 177 (PLUVICTO) treatment
☐	☒ +112 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #4 - Week 16. Lu 177 (PLUVICTO) treatment
☐	☒ +126 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #4 - Week 18. Lu 177 (PLUVICTO) treatment
☐	☒ +154 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #5 - Week 22. Lu 177 (PLUVICTO) treatment
☐	☒ +168 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #5 - Week 24. Lu 177 (PLUVICTO) treatment
☐	☒ +196 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #6 - Week 28. Lu 177 (PLUVICTO) treatment
☐	☒ +210 day Follow Up - Clinic - Radiation Oncology	As Per Special Instructions, Tumor Group: Genitourinary, Remote Provincial Clerk to Process ONLY. Prior to Dose #6 - Week 30. Lu 177 (PLUVICTO) treatment

Versioning: Yes

Jira: CST-379723

Protocols: SMILALD

Cycles/PowerPlans:

- ONC SM SMILALD (PO)
- ONCP SM SMILALD (PO)

Changes:

- Regimen name updated from ONC SM SMILALD (PO) to ONC SM SMILALD.
- Regimen updated to contain 8 cycles – 1 treatment per cycle, 2-4 weeks per cycle.
- PowerPlan name updated from ONCP SM SMILALD (PO) to ONCP SM SMILALD.

ONC SM SMILALD (Pending)

► Show additional details

+ Add Document Response View Responses

ONCP SM SMILALD - Cycle 1	*Est. Start Date: 07-Aug-2026
Start	Skip
ONCP SM SMILALD - Cycle 2	*Est. Start Date: 21-Aug-2026
ONCP SM SMILALD - Cycle 3	*Est. Start Date: 04-Sep-2026
ONCP SM SMILALD - Cycle 4	*Est. Start Date: 18-Sep-2026
ONCP SM SMILALD - Cycle 5	*Est. Start Date: 02-Oct-2026
ONCP SM SMILALD - Cycle 6	*Est. Start Date: 16-Oct-2026
ONCP SM SMILALD - Cycle 7	*Est. Start Date: 30-Oct-2026
ONCP SM SMILALD - Cycle 8	*Est. Start Date: 13-Nov-2026

New Prescription phase:

- **Aldesleukin** prescription order sentence updated to: *22 million_unit, intralesional, once oncology, syring-inj, Use Patient Supply.*
- **Aldesleukin** prescription order comment updated to: *Dispensed in 8 x 0.55 mL syringes. 5 million units/mL. For administration by ordering provider. Observe for 30 minutes post-treatment (not required after first treatment with no reaction).*
 - Note: Medical Staff can administer less if desired but full dose will be ordered each time

New In-Clinic Injections Phase:

Added yellow CDS note: *For patients who will be receiving doses in clinic.*

Added linked acetaminophen and aldesleukin orders to be selected for in-clinic administration.

- **Aldesleukin** medication order sentence updated to: *22 million_unit, intralesional, once oncology, syring-inj, Use Patient Supply.*
- **Aldesleukin** medication order comment updated to: *Dispensed in 8 x 0.55 mL syringes. 5 million units/mL. For administration by ordering provider. Observe for 30 minutes post-treatment (not required after first treatment with no reaction).*
- **Not** selected by default - Provider must select this phase for on-site administration. It can be left unselected if ordering for offsite administration.

View	Component	Status	Dose...	Details
ONCP SM SMILALD (Start Pending)	ONCP SM SMILALD - Cycle 1, Prescriptions (Future Pending)			
ONCP SM SMILALD - Cycle 1	Link to Protocol: Treatment of In-Transit Melanoma using Intralesional Aldesleukin (IL-2)			
Prescriptions (Future Pending)	Revised: 1 Sept 2026			
In-Clinic Injections (Day 1) (Future Pending)	Treatment Regimen			
Scheduling (Initiated Pending)	aldesleukin			22 million_unit, intralesional, as directed, drug form: inj, dispense qty: 1 vial Dispensed in 8 x 0.55 mL syringes. 5 million units/mL. For administration by ordering provider. Observe for 30 minutes post-trea...

View

Orders for Signature

- ONCP SM SMILALD (Start Pending)
- ONCP SM SMILALD - Cycle 1
- Prescriptions (Future Pending)
- In-Clinic Injections (Day 1) (Future Pending)
- Scheduling (Initiated Pending)

ONCP SM SMILALD - Cycle 1, In-Clinic Injections (Day 1) (Future Pending) *Est. 01-Jul-2026 08:00 PDT - 1 Days

Component	Day 1
Nursing Orders	Future Pending
For patients who will be receiving doses in clinic	*Est. 01-Jul-2026 08:00...
First treatment: vital signs pre and post treatment. Observe for 30 minutes post-treatment (not required after first treatment with no reaction)	Actions
Pre-Medications	
acetaminophen 325 mg, PO, once oncology, drug form: tab Between 30 and 60 minutes prior to treatment. Day 1	-30 min
Treatment Regimen	
Zero Time	0 hr
aldesleukin (aldesleukin - oncology) 22 million_unit, intraslesional, once oncology, drug form: inj, ... Dispensed in 8 x 0.55 mL syringes. 5 million units/mL. For ad...	Planned
Additional Orders	0 min
Any additional orders will be displayed below. Please review and adjust scheduled administration time as nee...	

Scheduling phase:

- Optional **Follow Up – Clinic – Oncology On Treatment** order for Medical Oncology with options: 2 weeks, 3 weeks and 4 weeks.
- The scheduling phase does **NOT** contain the in-clinic injection appointment order. Providers will continue to order this appointment as before to book into SDC, Task Clinic, etc.

View

Orders for Signature

- ONCP SM SMILALD (Start Pending)
- ONCP SM SMILALD - Cycle 1
- Prescriptions (Future Pending)
- In-Clinic Injections (Day 1) (Future Pending)
- Scheduling (Initiated Pending)

ONCP SM SMILALD - Cycle 1, Scheduling (Initiated Pending)

Component	Status	Dose	Details
Follow Up - Clinic - Oncology On Treatment			Follow Up: 2 weeks, Physician Specialty: Medical Oncology, Tumor Group: Skin and Melanoma

Changes for Providers:

- Providers will now order one treatment per cycle using the **aldesleukin prescription**.
 - Multiple cycles can be ordered if the physician wishes to order multiple treatments.
- If aldesleukin is to be administered **on site**, Providers must additionally select one of the linked medication orders in the **in-clinic injections phase**.
- Aside from Medical Oncology follow up's, continue to order follow-up orders outside the PowerPlan.
- Continue to book injection appointments outside the PowerPlan as before, when applicable.

Changes for Pharmacy Staff:

- Patient prescriptions will begin to appear on the **Pharmacy Oncology Review List** under the Rx Only view.

Start Date: 23-Jun-2026 End Date: 21-Jul-2026 Site: BC Cancer Vancouver Unit: All Units Show: Rx Only

Showing 30 per page SearchFilter All

Checklist	Patient Name	MRN	Est Start Date	Order Name	Order Status	CAP	Plan Name	Cycle	Clinical Check Completed	Lab Check Completed	Ordering Provider
	CRISBCC, LOBBY	780000441	25-JUN-2026 08:00	aldesleukin	Future	ONCP SM SMILALD	Cycle 1				

Showing 1 to 1 of 1 entries Previous 1 Next

- Patients will continue to appear on the perioperative tracking shell for SDC patients at BCC VA.
- On-site administrations will continue to be verified using the Medication Order in the In-Clinic Injections phase.

Versioning: Yes

Jira: CST-358140

Net New Protocols

Net New Protocols:

- ONC GI GIGAJDFLOD
- ONC GU GUBAJDUR
- ONC GO GOEAVDUCAT
- ONC LU LUSCDUR
- ONC GU GUBNADURPG
- ONC CN UCNVORA
- ONC MY UMYTECTOC Cycle 1 on Days 1, 3 and 5 Option
- ONC MY UMYTECTOC Cycle 1 on Days 1, 3 and 8 Option

- ONCP GI GIGAJDFLOD Neoadjuvant and Adjuvant Combination Phases Cycles 1 to 4
- ONCP GI GIGAJDFLOD Adjuvant Monotherapy Phase Cycles 5+
- ONCP GU GUBAJDUR Pretreatment Plan
- ONCP GU GUBAJDUR
- ONCP GU GUBNADURPG Pretreatment Plan
- ONCP GU GUBNADURPG CARBOplatin Option
- ONCP GU GUBNADURPG CISplatin Option
- ONCP GU GUBNADURPG CISplatin Split Dosing Option
- ONCP GO GOEAVDUCAT Cycles 1 to 6
- ONCP GO GOEAVDUCAT Cycles 7+
- ONCP LU LUSCDUR Pretreatment Plan
- ONCP LU LUSCDUR
- ONCP CN UCNVORA (PO) Pretreatment Plan
- ONCP CN UCNVORA (PO) Cycles 1 to 2
- ONCP CN UCNVORA (PO) Cycles 3 to 24
- ONCP CN UCNVORA (PO) Cycles 25+
- ONCP MY UMYTECTOC Prophylactic Tocilizumab Cycle 1 on Days 1, 3 and 5 Option
- ONCP MY UMYTECTOC Prophylactic Tocilizumab Cycle 1 on Days 1, 3 and 8 Option

Jira: CST-380193, CST-379795, CST-379794, CST-379793, CST-379081, CST-377372, CST-362586

Jira Ticket #	CST-378055, CST-376739, CST-380698, CST-379723, CST-358140 CST-380193, CST-379795, CST-379794, CST-379793, CST-379081, CST-377372, CST-362586
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Cerner Phone Support: 1-844-214-7444

